Chinese- REPORT SUMMARY
- TABLE OF CONTENTS
-
Benign Prostatic Hyperplasia Therapeutics market report explains the definition, types, applications, major countries, and major players of the Benign Prostatic Hyperplasia Therapeutics market. The report mainly contains different types, applications, and regional historical data from 2017-2021 and forecast data from 2022-2028.
The report contains qualitative and quantitative analysis of the entire industry.
The influence of COVID-19 has been considered in the report. Coronavirus Impact is included in Chapter 2. In addition, Strategic Analytics to Boost Productivity and Profitability is included in Chapter 3.
By Player:
Eli Lilly and Company
GlaxoSmithKline plc
Astellas Pharma
Teva Pharmaceutical Industries Limited
Allergan plc
Sanofi
Abbott Laboratories
Boehringer Ingelheim Pharma GmbH & Co KG
Merck & Co
Pfizer
By Type:
Alpha blocker
5-Alpha reductase inhibitor
Phosphodiesterase-5 inhibitor
Others
By End-User:
Mono drug therapy
Combination drug therapy
By Region:
North America
-
United States
-
Canada
-
Mexico
Europe
-
Germany
-
UK
-
Spain
-
France
-
Italy
-
Denmark
-
Finland
-
Norway
-
Sweden
-
Poland
-
Russia
-
Turkey
Asia-Pacific
-
China
-
Japan
-
India
-
South Korea
-
Pakistan
-
Bangladesh
-
Indonesia
-
Thailand
-
Singapore
-
Malaysia
-
Philippines
-
Vietnam
-
Others
South America
-
Brazil
-
Colombia
-
Chile
-
Argentina
-
Venezuela
-
Peru
-
Puerto Rico
-
Ecuador
-
Others
GCC
-
Bahrain
-
Kuwait
-
Oman
-
Qatar
-
Saudi Arabia
-
United Arab Emirates
Africa
-
Nigeria
-
South Africa
-
Egypt
-
Algeriat
-
Others
Oceania
-
Australia
-
New Zealand
TABLE OF CONTENT
1. Global Benign Prostatic Hyperplasia Therapeutics Executive Summary
-
1.1 Introduction
-
1.2 Market Panorama, 2022
2 Coronavirus Impact
-
2.1 Benign Prostatic Hyperplasia Therapeutics Outlook to 2028- Original Forecasts
-
2.2 Benign Prostatic Hyperplasia Therapeutics Outlook to 2028- COVID-19 Affected Forecasts
-
2.3 Impact on Industry
3 Strategic Analytics to Boost Productivity and Profitability
-
3.1 Potential Market Drivers and Opportunities
-
3.2 New Challenges and Strategies
-
3.3 Short Term and Long Term Benign Prostatic Hyperplasia Therapeutics Market Trends
4 Key Inferences
5 Market Overview
-
5.1 Current Market Scenario
-
5.2 Porter's Five Forces Analysis
-
5.2.1 Bargaining Power of Suppliers
-
5.2.2 Bargaining Power of Consumers
-
5.2.3 Threat of New Entrants
-
5.2.4 Threat of Substitute Product and Services
-
5.2.5 Competitive Rivalry within the Industry
6 Global Benign Prostatic Hyperplasia Therapeutics Market- Recent Developments
-
6.1 Benign Prostatic Hyperplasia Therapeutics Market News and Developments
-
6.2 Benign Prostatic Hyperplasia Therapeutics Market Deals Landscape
7 Benign Prostatic Hyperplasia Therapeutics Raw Materials and Cost Structure Analysis
-
7.1 Benign Prostatic Hyperplasia Therapeutics Key Raw Materials
-
7.2 Benign Prostatic Hyperplasia Therapeutics Price Trend of Key Raw Materials
-
7.3 Benign Prostatic Hyperplasia Therapeutics Key Suppliers of Raw Materials
-
7.4 Benign Prostatic Hyperplasia Therapeutics Market Concentration Rate of Raw Materials
-
7.5 Benign Prostatic Hyperplasia Therapeutics Cost Structure Analysis
-
7.5.1 Benign Prostatic Hyperplasia Therapeutics Raw Materials Analysis
-
7.5.2 Benign Prostatic Hyperplasia Therapeutics Labor Cost Analysis
-
7.5.3 Benign Prostatic Hyperplasia Therapeutics Manufacturing Expenses Analysis
8 Global Benign Prostatic Hyperplasia Therapeutics Import and Export Analysis (Top 10 Countries)
-
8.1 Global Benign Prostatic Hyperplasia Therapeutics Import by Region (Top 10 Countries) (2017-2028)
-
8.2 Global Benign Prostatic Hyperplasia Therapeutics Export by Region (Top 10 Countries) (2017-2028)
9 Global Benign Prostatic Hyperplasia Therapeutics Market Outlook by Types and Applications to 2022
-
9.1 Global Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate by Type (2017-2022)
-
9.1.1 Global Alpha blocker Consumption and Growth Rate (2017-2022)
-
9.1.2 Global 5-Alpha reductase inhibitor Consumption and Growth Rate (2017-2022)
-
9.1.3 Global Phosphodiesterase-5 inhibitor Consumption and Growth Rate (2017-2022)
-
9.1.4 Global Others Consumption and Growth Rate (2017-2022)
-
9.2 Global Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate by Application (2017-2022)
-
9.2.1 Global Mono drug therapy Consumption and Growth Rate (2017-2022)
-
9.2.2 Global Combination drug therapy Consumption and Growth Rate (2017-2022)
10 Region and Country-wise Benign Prostatic Hyperplasia Therapeutics Market Analysis and Outlook till 2022
-
10.1 Global Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.2 North America Consumption Analysis
-
10.2.1 United States Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.2.2 Canada Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.2.3 Mexico Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3 Europe Consumption Analysis
-
10.3.1 Germany Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.2 UK Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.3 Spain Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.4 Belgium Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.5 France Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.6 Italy Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.7 Denmark Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.8 Finland Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.9 Norway Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.10 Sweden Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.11 Poland Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.12 Russia Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.3.13 Turkey Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4 APAC Consumption Analysis
-
10.4.1 China Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4.2 Japan Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4.3 India Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4.4 South Korea Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4.5 Pakistan Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4.6 Bangladesh Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4.7 Indonesia Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4.8 Thailand Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4.9 Singapore Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4.10 Malaysia Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4.11 Philippines Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.4.12 Vietnam Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.5 South America Consumption Analysis
-
10.5.1 Brazil Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.5.2 Colombia Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.5.3 Chile Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.5.4 Argentina Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.5.5 Venezuela Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.5.6 Peru Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.5.7 Puerto Rico Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.5.8 Ecuador Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.6 GCC Consumption Analysis
-
10.6.1 Bahrain Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.6.2 Kuwait Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.6.3 Oman Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.6.4 Qatar Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.6.5 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.6.6 United Arab Emirates Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.7 Africa Consumption Analysis
-
10.7.1 Nigeria Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.7.2 South Africa Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.7.3 Egypt Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.7.4 Algeria Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.8 Oceania Consumption Analysis
-
10.8.1 Australia Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
-
10.8.2 New Zealand Benign Prostatic Hyperplasia Therapeutics Consumption (2017-2022)
11 Global Benign Prostatic Hyperplasia Therapeutics Competitive Analysis
-
11.1 Eli Lilly and Company
-
11.1.1 Eli Lilly and Company Company Details
-
11.1.2 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.1.3 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
11.1.4 Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
11.1.5 Recent Research and Development Strategies
-
11.2 GlaxoSmithKline plc
-
11.2.1 GlaxoSmithKline plc Company Details
-
11.2.2 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.2.3 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
11.2.4 GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
11.2.5 Recent Research and Development Strategies
-
11.3 Astellas Pharma
-
11.3.1 Astellas Pharma Company Details
-
11.3.2 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.3.3 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
11.3.4 Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
11.3.5 Recent Research and Development Strategies
-
11.4 Teva Pharmaceutical Industries Limited
-
11.4.1 Teva Pharmaceutical Industries Limited Company Details
-
11.4.2 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.4.3 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
11.4.4 Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
11.4.5 Recent Research and Development Strategies
-
11.5 Allergan plc
-
11.5.1 Allergan plc Company Details
-
11.5.2 Allergan plc Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.5.3 Allergan plc Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
11.5.4 Allergan plc Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
11.5.5 Recent Research and Development Strategies
-
11.6 Sanofi
-
11.6.1 Sanofi Company Details
-
11.6.2 Sanofi Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.6.3 Sanofi Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
11.6.4 Sanofi Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
11.6.5 Recent Research and Development Strategies
-
11.7 Abbott Laboratories
-
11.7.1 Abbott Laboratories Company Details
-
11.7.2 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.7.3 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
11.7.4 Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
11.7.5 Recent Research and Development Strategies
-
11.8 Boehringer Ingelheim Pharma GmbH & Co KG
-
11.8.1 Boehringer Ingelheim Pharma GmbH & Co KG Company Details
-
11.8.2 Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.8.3 Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
11.8.4 Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
11.8.5 Recent Research and Development Strategies
-
11.9 Merck & Co
-
11.9.1 Merck & Co Company Details
-
11.9.2 Merck & Co Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.9.3 Merck & Co Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
11.9.4 Merck & Co Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
11.9.5 Recent Research and Development Strategies
-
11.10 Pfizer
-
11.10.1 Pfizer Company Details
-
11.10.2 Pfizer Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
11.10.3 Pfizer Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
11.10.4 Pfizer Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
11.10.5 Recent Research and Development Strategies
12 Global Benign Prostatic Hyperplasia Therapeutics Market Outlook by Types and Applications to 2028
-
12.1 Global Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate by Type (2022-2028)
-
12.1.1 Global Alpha blocker Consumption Forecast and Growth Rate (2022-2028)
-
12.1.2 Global 5-Alpha reductase inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
12.1.3 Global Phosphodiesterase-5 inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
12.1.4 Global Others Consumption Forecast and Growth Rate (2022-2028)
-
12.2 Global Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate by Application (2022-2028)
-
12.2.1 Global Mono drug therapy Consumption Forecast and Growth Rate (2022-2028)
-
12.2.2 Global Combination drug therapy Consumption Forecast and Growth Rate (2022-2028)
13 Country-wise Benign Prostatic Hyperplasia Therapeutics Market Analysis and Outlook to 2028
-
13.1 Global Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.2 North America Consumption Analysis
-
13.2.1 United States Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.2.2 Canada Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.2.3 Mexico Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3 Europe Consumption Analysis
-
13.3.1 Germany Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.2 UK Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.3 Spain Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.4 Belgium Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.5 France Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.6 Italy Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.7 Denmark Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.8 Finland Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.9 Norway Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.10 Sweden Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.11 Poland Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.12 Russia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.3.13 Turkey Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4 APAC Consumption Analysis
-
13.4.1 China Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4.2 Japan Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4.3 India Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4.4 South Korea Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4.5 Pakistan Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4.6 Bangladesh Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4.7 Indonesia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4.8 Thailand Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4.9 Singapore Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4.10 Malaysia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4.11 Philippines Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.4.12 Vietnam Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.5 South America Consumption Analysis
-
13.5.1 Brazil Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.5.2 Colombia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.5.3 Chile Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.5.4 Argentina Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.5.5 Venezuela Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.5.6 Peru Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.5.7 Puerto Rico Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.5.8 Ecuador Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.6 GCC Consumption Analysis
-
13.6.1 Bahrain Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.6.2 Kuwait Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.6.3 Oman Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.6.4 Qatar Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.6.5 Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.6.6 United Arab Emirates Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.7 Africa Consumption Analysis
-
13.7.1 Nigeria Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.7.2 South Africa Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.7.3 Egypt Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.7.4 Algeria Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.8 Oceania Consumption Analysis
-
13.8.1 Australia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
-
13.8.2 New Zealand Benign Prostatic Hyperplasia Therapeutics Consumption Forecast (2022-2028)
14 Conclusions
The List of Tables and Figures
-
Table Definition of Benign Prostatic Hyperplasia Therapeutics
-
Figure of Benign Prostatic Hyperplasia Therapeutics Picture
-
Table Global Benign Prostatic Hyperplasia Therapeutics Import by Region (Top 10 Countries) (2017-2028)
-
Table Global Benign Prostatic Hyperplasia Therapeutics Export by Region (Top 10 Countries) (2017-2028)
-
Figure Global Alpha blocker Consumption and Growth Rate (2017-2022)
-
Figure Global 5-Alpha reductase inhibitor Consumption and Growth Rate (2017-2022)
-
Figure Global Phosphodiesterase-5 inhibitor Consumption and Growth Rate (2017-2022)
-
Figure Global Others Consumption and Growth Rate (2017-2022)
-
Figure Global Mono drug therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Combination drug therapy Consumption and Growth Rate (2017-2022)
-
Figure Global Benign Prostatic Hyperplasia Therapeutics Consumption by Country (2017-2022)
-
Table North America Benign Prostatic Hyperplasia Therapeutics Consumption by Country (2017-2022)
-
Figure United States Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Canada Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Mexico Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Europe Benign Prostatic Hyperplasia Therapeutics Consumption by Country (2017-2022)
-
Figure Germany Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure UK Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Spain Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Belgium Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure France Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Italy Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Denmark Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Finland Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Norway Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Sweden Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Poland Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Russia Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Turkey Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Table APAC Benign Prostatic Hyperplasia Therapeutics Consumption by Country (2017-2022)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Japan Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure India Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Korea Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Pakistan Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Bangladesh Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Indonesia Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Thailand Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Singapore Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Malaysia Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Philippines Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Vietnam Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Table South America Benign Prostatic Hyperplasia Therapeutics Consumption by Country (2017-2022)
-
Figure Brazil Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Colombia Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Chile Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Argentina Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Venezuela Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Peru Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Puerto Rico Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Ecuador Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Table GCC Benign Prostatic Hyperplasia Therapeutics Consumption by Country (2017-2022)
-
Figure Bahrain Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Kuwait Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Oman Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Qatar Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure United Arab Emirates Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Africa Benign Prostatic Hyperplasia Therapeutics Consumption by Country (2017-2022)
-
Figure Nigeria Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure South Africa Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Egypt Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure Algeria Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Oceania Benign Prostatic Hyperplasia Therapeutics Consumption by Country (2017-2022)
-
Figure Australia Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Figure New Zealand Benign Prostatic Hyperplasia Therapeutics Consumption and Growth Rate (2017-2022)
-
Table Eli Lilly and Company Company Details
-
Table Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
Table Eli Lilly and Company Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
Table GlaxoSmithKline plc Company Details
-
Table GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
Table GlaxoSmithKline plc Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
Table Astellas Pharma Company Details
-
Table Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
Table Astellas Pharma Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
Table Teva Pharmaceutical Industries Limited Company Details
-
Table Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
Table Teva Pharmaceutical Industries Limited Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
Table Allergan plc Company Details
-
Table Allergan plc Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Allergan plc Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
Table Allergan plc Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
Table Sanofi Company Details
-
Table Sanofi Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Sanofi Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
Table Sanofi Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
Table Abbott Laboratories Company Details
-
Table Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
Table Abbott Laboratories Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
Table Boehringer Ingelheim Pharma GmbH & Co KG Company Details
-
Table Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
Table Boehringer Ingelheim Pharma GmbH & Co KG Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
Table Merck & Co Company Details
-
Table Merck & Co Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Merck & Co Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
Table Merck & Co Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
Table Pfizer Company Details
-
Table Pfizer Benign Prostatic Hyperplasia Therapeutics Sales, Price, Value and Gross Profit (2017-2022)
-
Table Pfizer Benign Prostatic Hyperplasia Therapeutics Main Business and Markets Served
-
Table Pfizer Benign Prostatic Hyperplasia Therapeutics Product Portfolio
-
Figure Global Alpha blocker Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global 5-Alpha reductase inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Phosphodiesterase-5 inhibitor Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Others Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Mono drug therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Combination drug therapy Consumption Forecast and Growth Rate (2022-2028)
-
Figure Global Benign Prostatic Hyperplasia Therapeutics Consumption Forecast by Country (2022-2028)
-
Table North America Benign Prostatic Hyperplasia Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure United States Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Canada Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Mexico Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Europe Benign Prostatic Hyperplasia Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Germany Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure UK Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Spain Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Belgium Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure France Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Italy Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Denmark Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Finland Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Norway Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Sweden Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Poland Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Russia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Turkey Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table APAC Benign Prostatic Hyperplasia Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure China Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Japan Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure India Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Korea Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Pakistan Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Bangladesh Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Indonesia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Thailand Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Singapore Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Malaysia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Philippines Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Vietnam Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table South America Benign Prostatic Hyperplasia Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Brazil Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Colombia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Chile Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Argentina Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Venezuela Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Peru Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Puerto Rico Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Ecuador Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table GCC Benign Prostatic Hyperplasia Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Bahrain Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Kuwait Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Oman Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Qatar Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Saudi Arabia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure United Arab Emirates Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Africa Benign Prostatic Hyperplasia Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Nigeria Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure South Africa Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Egypt Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure Algeria Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Table Oceania Benign Prostatic Hyperplasia Therapeutics Consumption Forecast by Country (2022-2028)
-
Figure Australia Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
Figure New Zealand Benign Prostatic Hyperplasia Therapeutics Consumption Forecast and Growth Rate (2022-2028)
-
